Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 70 years of age , with ≥ 40Kg~* Histological or cytological confirmed colorectal cancer~* ECOG performance status of 0-1~* Standard regimen failed or no standard regimen available~* Adequate hepatic, renal, heart, and hematologic functions~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Signed and dated informed consent.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure~Exclusion Criteria:~* Pregnant or lactating women~* Any factors that influence the usage of oral administration~* Evidence of CNS metastasis~* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial~* Previous treatment with VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Proteinuria ≥ 2+ (1.0g/24hr)~* Uncontrolled hemorrhage in GI~* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A- 4mg QD (Type: EXPERIMENTAL): arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
- B- 5mg once daily, 3wks on/1wk off (Type: EXPERIMENTAL): arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).